查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
肿瘤生物仿製药市场与 COVID-19 影响分析，按药物类别、癌症类型、分销渠道、国家和地区 - 2023-2030 年行业分析、市场规模、市场份额和预测
市场调查报告书
商品编码
1339905

肿瘤生物仿製药市场与 COVID-19 影响分析，按药物类别、癌症类型、分销渠道、国家和地区 - 2023-2030 年行业分析、市场规模、市场份额和预测

Oncology Biosimilars Market with COVID-19 Impact Analysis, By Drug Class, By Type of Cancer, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 302 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2022年肿瘤生物仿製药市场规模为420012万美元，2023年至2030年復合年增长率为10.67%。

肿瘤生物仿製药市场-市场动态：

  • 癌症患病率增加。
  • 癌症发病率的上升是推动肿瘤生物仿製药市场的主要因素。国际癌症研究机构 (IARC) 预测，到 2040 年，全球将有 1630 万人死于癌症，新诊断癌症人数将达到 2750 万人。正常细胞经历一个多阶段的过程，通常从癌前病变到癌症开始时的恶性肿瘤。除了正常的风险积累之外，老年人的细胞修復系统通常效率较低。吸烟、饮酒、不良饮食、缺乏运动以及空气污染都会增加患癌症的风险。

肿瘤生物仿製药市场 - 主要见解：

  • 根据我们的研究分析师分享的分析，全球肿瘤生物仿製药市场预计在预测期内（2023-2030）每年将以 10.67% 左右的复合年增长率增长
  • 由于癌症患病率不断上升，肿瘤生物仿製药行业预计将以显着的速度增长
  • 根据药物类别细分，预计 G-CSF 将在 2022 年呈现最大市场份额
  • 根据癌症类型，乳腺癌是 2022 年的主要癌症类型
  • 从分销渠道细分来看，2022年医院零售为主导类型
  • 按地区划分，北美是 2022 年的主要收入来源

肿瘤生物仿製药市场-細項分析：

  • 全球肿瘤生物仿製药市场根据药物类别、癌症类型、分销渠道和地区进行细分。
  • 市场根据药物类别分为几类：单克隆抗体、G-CSF、造血剂等。 G-CSF 较高的市场份额是化疗后广泛使用 G-CSF 来帮助癌症治疗后白细胞恢復的结果。粒细胞集落刺激因子 (G-CSF) 有多种形式，包括非格司亭、来格司亭、长效非格司亭和聚乙二醇非格司亭。
  • 市场根据癌症类型分为几类：乳腺癌、肺癌、胃癌、前列腺癌、宫颈癌、血癌、脑癌等。由于乳腺癌病例在全球所有恶性肿瘤中所占比例最高，因此乳腺癌行业占据了市场主导地位。许多变量都会增加患乳腺癌的风险，包括年龄、肥胖、酗酒、吸烟、绝经后激素治疗、辐射史和疾病家族史。

肿瘤生物仿製药市场 - 地理洞察：

从地域上看，该市场广泛分布于北美、拉丁美洲、欧洲、亚太地区以及中东和非洲地区。这些区域根据开展业务的国家进一步划分。亚太地区是一个发展中市场，尤其是韩国、中国和印度，在癌症生物仿製药方面取得了长足的进步。由于人口众多，健康意识不断增强，医疗保健支出不断增加，製造成本下降，也反映了市场未来的潜力。

肿瘤生物仿製药市场-竞争格局：

公司通过多种渠道销售产品，包括企业网站、电子商务网站、零售商、分销商和最终消费者。产品製造商在多个方面进行竞争，包括产品成本、性能、产品製造、分销渠道、声誉和可用性。企业用来扩大影响力和扩大市场份额的一些主要技术包括新产品发布、分销网络开发、研发支出以及併购。例如，2022 年 5 月，Biocon Biologics 和 Viatris 生产的第三种癌症生物仿製药 Abevmy（贝伐珠单抗）已在加拿大上市。

最近的发展：

2022 年 9 月，Celltrion USA 获得 FDA 许可，使用其肿瘤生物仿製药 vegzelma (bevacizumab-add) 治疗六种不同形式的癌症。

该研究的主要特点：

  • 这项关于肿瘤生物仿製药市场的拟议研究提供了市场规模（百万美元）、年复合成长率（CAGR%）和预测估计（2023-2030），以 2022 年为基准年
  • 该报告为客户提供有关肿瘤生物仿製药市场的最新趋势见解。
  • 该研究报告阐明了不同细分市场/国家的潜在增长机会，并解释了肿瘤生物仿製药市场有吸引力的投资主张矩阵
  • 总体报告确定了新的投资机会、老牌参与者面临的挑战以及肿瘤生物仿製药市场维持的增长因素
  • COVID-19 对肿瘤生物仿製药市场规模、预测、复合年增长率和市场动态的影响将在研究范围下详细讨论。还将涵盖对新冠疫情后肿瘤生物仿製药市场的详细见解。
  • 为了让本报告的用户全面了解肿瘤生物仿製药市场，我们还对肿瘤生物仿製药市场的竞争格局和关键创新者进行了分析。
  • 该研究包括增长前景映射分析，其中所有行业细分都根据其市场规模、增长率和吸引力进行基准测试。
  • 该报告提供了主要市场参与者的详细公司概况，这将帮助用户了解在肿瘤生物仿製药市场运营的参与者的财务信息和战略倡议。
  • 此外，报告还揭示了全球和区域市场主要参与者的重要收购和兼併、合作和合资、新产品推出、研发、区域扩张。
  • 全球肿瘤生物仿製药市场报告主要面向该行业的各个利益相关者，包括供应商、投资者、新进入者、分销商和财务分析师

目录

第 1 章：肿瘤生物仿製药市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按药物类别分類的肿瘤生物仿製药市场片段
    • 按癌症类型分類的肿瘤生物仿製药市场片段
    • 按分销渠道分類的肿瘤生物仿製药市场片段
    • 按国家/地区分類的肿瘤生物仿製药市场摘要
    • 按地区分類的肿瘤生物仿製药市场片段
  • 竞争洞察

第 3 章：肿瘤生物仿製药主要市场趋势

  • 肿瘤生物仿製药市场驱动因素
    • 市场驱动因素的影响分析
  • 肿瘤生物仿製药市场限制
    • 市场限制影响分析
  • 肿瘤生物仿製药市场机会
  • 肿瘤生物仿製药市场未来趋势

第 4 章：肿瘤生物仿製药行业研究

  • PEST分析
  • 波特五力分析
  • 增长前景图
  • 规范架构分析

第 5 章：肿瘤生物仿製药市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的细分市场
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：肿瘤生物仿製药市场格局

  • 2022 年肿瘤生物仿製药市场份额分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：肿瘤生物仿製药市场 - 按药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 单克隆抗体
    • 粒细胞集落刺激因子
    • 造血剂
    • 其他的

第 8 章：肿瘤生物仿製药市场 - 按癌症类型

  • 概述
    • 按癌症类型分類的细分市场份额分析
    • 乳癌
    • 肺癌
    • 胃癌
    • 前列腺癌
    • 宫颈癌
    • 血癌
    • 脑癌
    • 其他的

第 9 章：肿瘤生物仿製药市场 - 按分销渠道

  • 概述
    • 按分销渠道分類的细分市场份额分析
    • 零售药店
    • 医院药房
    • 网上药店

第 10 章：肿瘤生物仿製药市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场份额分析
  • 北美
    • 概述
    • 北美肿瘤生物仿製药主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按药物类别）
    • 北美市场规模和预测（按癌症类型）
    • 北美市场规模和预测（按分销渠道）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲肿瘤生物仿製药主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按药物类别）
    • 欧洲市场规模和预测（按癌症类型）
    • 欧洲市场规模和预测（按分销渠道）
    • 德国
    • 意大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区肿瘤生物仿製药主要製造商
    • 亚太地区市场规模和预测（按国家）
    • 亚太地区市场规模和预测（按药物类别）
    • 亚太地区市场规模和预测（按癌症类型）
    • 亚太地区市场规模和预测（按分销渠道）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳大利亚
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉美
    • 概述
    • 拉丁美洲肿瘤生物仿製药主要製造商
    • 拉丁美洲市场规模和预测（按国家）
    • 拉丁美洲市场规模和预测（按药物类别）
    • 拉丁美洲市场规模和预测（按癌症类型）
    • 拉丁美洲市场规模和预测（按分销渠道）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 肿瘤生物仿製药中东和非洲的主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按药物类别）
    • 中东和非洲市场规模及预测（按癌症类型）
    • 中东和非洲市场规模及预测（按分销渠道）
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 以色列
    • 火鸡
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 肿瘤生物仿製药行业

  • 竞争仪表板
  • 公司简介
    • Teva Pharmaceuticals
    • STADA Arzneimittel AG
    • Shanghai Henlius Biotech
    • Sandoz (Novartis)
    • Samsung Bioepis
    • Pfizer
    • Pfenex Inc.
    • Mylan
    • Innovent Biologics
    • Dr. Reddy's Laboratories
    • Celltrion Healthcare
    • Biocon
    • Apotex
    • Amgen
    • Accord Healthcare

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法论
  • 参考
  • 缩写
  • 免责声明
  • 联繫我们
Product Code: ANV1629

REPORT HIGHLIGHT

Oncology Biosimilars Market size was valued at USD 4,200.12 Million in 2022, expanding at a CAGR of 10.67% from 2023 to 2030.

Oncology biosimilars are biological medicines created to be strikingly comparable to and functionally equal to the oncology reference biologics, which are currently available in pharmaceuticals. These biosimilars are created to offer affordable cancer therapy choices. They go through thorough comparative tests to show that they are comparable in terms of safety, quality, and efficacy. Oncology biosimilars seek to improve patient access to essential cancer treatments while also perhaps lowering healthcare costs by providing therapeutic results that are equivalent to those of the unique oncology biologics. A comprehensive regulatory review is required for their approval to guarantee patient safety and maintain cancer treatment requirements.

Oncology Biosimilars Market- Market Dynamics:

  • Increasing prevalence of cancer.
  • The rising incidence of cancer is the primary factor driving the market for oncology biosimilars. The International Agency for Research on Cancer (IARC) predicts that by 2040, there would be 16.3 million cancer-related deaths globally and 27.5 million new cancer diagnoses. Normal cells go through a multi-stage process that normally goes from a pre-cancerous lesions to a tumor that is malignant when cancer begins. Aging persons often have less effective cellular repair systems in addition to the normal risk buildup. Smoking, consuming alcohol, adopting a poor diet, leading a life of inactivity, and air pollution all increase the chance of developing cancer.

Oncology Biosimilars Market- Key Insights:

  • As per the analysis shared by our research analyst, the global Oncology Biosimilars market is estimated to grow annually at a CAGR of around 10.67% over the forecast period (2023-2030)
  • The Oncology Biosimilars industry is projected to grow at a significant rate due to the growing prevalence of cancer
  • Based on drug class segmentation, G-CSF was predicted to show maximum market share in the year 2022
  • Based on type of cancer, breast cancer was the leading type in 2022
  • Based on distribution channel segmentation, hospital retail was the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

Oncology Biosimilars Market- Segmentation Analysis:

  • The Global Oncology Biosimilars Market is segmented on the basis of Drug Class, Type of Cancer, Distribution Channel, and Region.
  • The market is divided into categories based on Drug Class: monoclonal antibodies, G-CSF, hematopoietic agents, and others. The higher market share of G-CSF is a result of the widespread use of G-CSF after chemotherapy to aid in the recovery of white blood cells following cancer treatment. Granulocyte colony-stimulating factors (G-CSF) are available in a variety of forms, including filgrastim, lenograstim, long-acting filgrastim, and pegfilgrastim.
  • The market is divided into categories based on type of cancer: breast cancer, lung cancer, stomach cancer, prostate cancer, cervical cancer, blood cancer, brain cancer, and others. Due to the highest percentage of breast cancer cases globally among all malignancies, the breast cancer sector commands the market. The risk of breast cancer is increased by a number of variables, including age, obesity, alcoholism, cigarette use, postmenopausal hormone treatment, exposure to radiation history, and family history of the disease.

Oncology Biosimilars Market- Geographical Insights:

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. The Asia Pacific region is a developing market, with Korea, China, and India, in particular, making strides with cancer biosimilars. Due to a large population, rising health consciousness, rising healthcare expenditure, and decreased manufacturing costs, they also reflect the market's future potential.

Oncology Biosimilars Market- Competitive Landscape:

Companies sell their products through a variety of channels, including corporate websites, e-commerce websites, retailers, distributors, and end consumers. Products makers compete on a variety of aspects, including product costs, performance, product making, Distribution Channel, reputation, and availability. Some of the primary techniques used by corporations to strengthen their reach and expand their market share include new product launches, distribution network development, R&D spending, and mergers and acquisitions. For instance, May 2022, Abevmy (bevacizumab), the third cancer biosimilar produced by Biocon Biologics and Viatris, has made accessible in Canada.

Recent Developments:

September 2022, Celltrion USA received FDA permission for using its oncology biosimilar vegzelma (bevacizumab-add) to treat six different forms of cancer.

Key features of the study:

  • This proposed research study on Oncology Biosimilars market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
  • The report provides the client the latest up-to-date and trending insights about the Oncology Biosimilars market.
  • The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Oncology Biosimilars market
  • The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Oncology Biosimilars market
  • Impact of COVID-19 on Oncology Biosimilars market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Oncology Biosimilars market post-COVID will also be covered.
  • In order to give the users of this report a comprehensive view on the Oncology Biosimilars market, we have also included competitive landscape and key innovator analysis for the Oncology Biosimilars market.
  • The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
  • The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Oncology Biosimilars market.
  • In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
  • The global Oncology Biosimilars market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ONCOLOGY BIOSIMILARS MARKET KEY PLAYERS

  • Teva Pharmaceuticals
  • STADA Arzneimittel AG
  • Shanghai Henlius Biotech
  • Sandoz (Novartis)
  • Samsung Bioepis
  • Pfizer
  • Pfenex Inc.
  • Mylan
  • Innovent Biologics
  • Dr. Reddy's Laboratories
  • Celltrion Healthcare
  • Biocon
  • Apotex
  • Amgen
  • Accord Healthcare

GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DRUG CLASS

  • Monoclonal Antibodies
  • G-CSF
  • Hematopoietic Agents
  • Others

GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY TYPE OF CANCER

  • Breast Cancer
  • Lung Cancer
  • Stomach Cancer
  • Prostate Cancer
  • Cervical Cancer
  • Blood Cancer
  • Brain Cancer
  • Others

GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Oncology Biosimilars Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Oncology Biosimilars Market Snippet by Drug Class
    • 2.1.2. Oncology Biosimilars Market Snippet by Type of Cancer
    • 2.1.3. Oncology Biosimilars Market Snippet by Distribution Channel
    • 2.1.4. Oncology Biosimilars Market Snippet by Country
    • 2.1.5. Oncology Biosimilars Market Snippet by Region
  • 2.2. Competitive Insights

3. Oncology Biosimilars Key Market Trends

  • 3.1. Oncology Biosimilars Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Oncology Biosimilars Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Oncology Biosimilars Market Opportunities
  • 3.4. Oncology Biosimilars Market Future Trends

4. Oncology Biosimilars Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Oncology Biosimilars Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Oncology Biosimilars Market Landscape

  • 6.1. Oncology Biosimilars Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Oncology Biosimilars Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
    • 7.1.2. Monoclonal Antibodies
    • 7.1.3. G-CSF
    • 7.1.4. Hematopoietic Agents
    • 7.1.5. Others

8. Oncology Biosimilars Market - By Type of Cancer

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type of Cancer, 2022 & 2030 (%)
    • 8.1.2. Breast Cancer
    • 8.1.3. Lung Cancer
    • 8.1.4. Stomach Cancer
    • 8.1.5. Prostate Cancer
    • 8.1.6. Cervical Cancer
    • 8.1.7. Blood Cancer
    • 8.1.8. Brain Cancer
    • 8.1.9. Others

9. Oncology Biosimilars Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
    • 9.1.2. Retail Pharmacies
    • 9.1.3. Hospital Pharmacies
    • 9.1.4. Online Pharmacies

10. Oncology Biosimilars Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Oncology Biosimilars Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Oncology Biosimilars Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Oncology Biosimilars Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Oncology Biosimilars Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Oncology Biosimilars Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Oncology Biosimilars Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Teva Pharmaceuticals
    • 11.2.2. STADA Arzneimittel AG
    • 11.2.3. Shanghai Henlius Biotech
    • 11.2.4. Sandoz (Novartis)
    • 11.2.5. Samsung Bioepis
    • 11.2.6. Pfizer
    • 11.2.7. Pfenex Inc.
    • 11.2.8. Mylan
    • 11.2.9. Innovent Biologics
    • 11.2.10. Dr. Reddy's Laboratories
    • 11.2.11. Celltrion Healthcare
    • 11.2.12. Biocon
    • 11.2.13. Apotex
    • 11.2.14. Amgen
    • 11.2.15. Accord Healthcare

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Oncology Biosimilars Market: Drug Class Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Oncology Biosimilars Market, by Drug Class 2018-2030 (USD Million)
  • TABLE Oncology Biosimilars Market: Type of Cancer Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Type of Cancer
  • TABLE Global Oncology Biosimilars Market, by Type of Cancer 2018-2030 (USD Million)
  • TABLE Oncology Biosimilars Market: Distribution Channel Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Oncology Biosimilars Market, by Distribution Channel 2018-2030 (USD Million)
  • TABLE Oncology Biosimilars Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Oncology Biosimilars Market, by Region 2018-2030 (USD Million)
  • TABLE North America Oncology Biosimilars Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Oncology Biosimilars Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE North America Oncology Biosimilars Market, by Type of Cancer, 2018-2030 (USD Million)
  • TABLE North America Oncology Biosimilars Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Europe Oncology Biosimilars Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Oncology Biosimilars Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Europe Oncology Biosimilars Market, by Type of Cancer, 2018-2030 (USD Million)
  • TABLE Europe Oncology Biosimilars Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Asia Pacific Oncology Biosimilars Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Oncology Biosimilars Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Asia Pacific Oncology Biosimilars Market, by Type of Cancer, 2018-2030 (USD Million)
  • TABLE Asia Pacific Oncology Biosimilars Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Latin America Oncology Biosimilars Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Oncology Biosimilars Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Latin America Oncology Biosimilars Market, by Type of Cancer, 2018-2030 (USD Million)
  • TABLE Latin America Oncology Biosimilars Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Oncology Biosimilars Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Oncology Biosimilars Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Oncology Biosimilars Market, by Type of Cancer, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Oncology Biosimilars Market, by Distribution Channel, 2018-2030 (USD Million)

List of Figures

  • FIGURE Oncology Biosimilars Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Drug Class segment market share analysis, 2022 & 2030
  • FIGURE Drug Class segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Type of Cancer segment market share analysis, 2022 & 2030
  • FIGURE Type of Cancer segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Distribution Channel segment market share analysis, 2022 & 2030
  • FIGURE Distribution Channel segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022 & 2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Oncology Biosimilars Market share and leading players, 2022
  • FIGURE Europe Oncology Biosimilars Market share and leading players, 2022
  • FIGURE Asia Pacific Oncology Biosimilars Market share and leading players, 2022
  • FIGURE Latin America Oncology Biosimilars Market share and leading players, 2022
  • FIGURE Middle East and Africa Oncology Biosimilars Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Oncology Biosimilars Market share analysis by country, 2022
  • FIGURE Germany Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Oncology Biosimilars Market share analysis by country, 2022
  • FIGURE India Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Oncology Biosimilars Market share analysis by country, 2022
  • FIGURE Brazil Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Oncology Biosimilars Market share analysis by country, 2022
  • FIGURE Saudi Arabia Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)